Table 4

Risk of sclerosis in patients with chronic GVHD, according to HLA-DPA1∼DPB1 haplotypes in donors and recipients

GenomeHaplotype*FrequencyNo. with haplotype/total (%)UnadjustedAdjusted
HR (95% CI)PHR (95% CI)P
Donor DPA1*01:03∼DPB1*04:01 0.40 492/808 (63) 1.24 (0.92-1.68) .16 1.23 (0.90-1.67) .19 
Recipient DPA1*01:03∼DPB1*04:01 0.40 501/778 (62) 1.53 (1.10-2.12) .01 1.54 (1.10-2.15) .01 
Donor DPA1*01:03∼DPB1*02:01 0.14 191/808 (25) 0.79 (0.56-1.11) .17 0.84 (0.60-1.18) .32 
Recipient DPA1*01:03∼DPB1*02:01 0.13 207/778 (26) 0.93 (0.66-1.31) .67 0.97 (0.69-1.38) .88 
Donor DPA1*01:03∼DPB1*04:02 0.11 160/808 (21) 0.90 (0.63-1.28) .56 0.87 (0.61-1.25) .45 
Recipient DPA1*01:03∼DPB1*04:02 0.11 168/778 (21) 0.80 (0.55-1.18) .27 0.77 (0.53-1.13) .19 
Donor DPA1*01:03∼DPB1*03:01 0.08 118/808 (15) 0.99 (0.68-1.47) .95 0.96 (0.64-1.42) .82 
Recipient DPA1*01:03∼DPB1*03:01 0.08 128/778 (16) 1.02 (0.68-1.54) .93 0.91 (0.60-1.37) .64 
GenomeHaplotype*FrequencyNo. with haplotype/total (%)UnadjustedAdjusted
HR (95% CI)PHR (95% CI)P
Donor DPA1*01:03∼DPB1*04:01 0.40 492/808 (63) 1.24 (0.92-1.68) .16 1.23 (0.90-1.67) .19 
Recipient DPA1*01:03∼DPB1*04:01 0.40 501/778 (62) 1.53 (1.10-2.12) .01 1.54 (1.10-2.15) .01 
Donor DPA1*01:03∼DPB1*02:01 0.14 191/808 (25) 0.79 (0.56-1.11) .17 0.84 (0.60-1.18) .32 
Recipient DPA1*01:03∼DPB1*02:01 0.13 207/778 (26) 0.93 (0.66-1.31) .67 0.97 (0.69-1.38) .88 
Donor DPA1*01:03∼DPB1*04:02 0.11 160/808 (21) 0.90 (0.63-1.28) .56 0.87 (0.61-1.25) .45 
Recipient DPA1*01:03∼DPB1*04:02 0.11 168/778 (21) 0.80 (0.55-1.18) .27 0.77 (0.53-1.13) .19 
Donor DPA1*01:03∼DPB1*03:01 0.08 118/808 (15) 0.99 (0.68-1.47) .95 0.96 (0.64-1.42) .82 
Recipient DPA1*01:03∼DPB1*03:01 0.08 128/778 (16) 1.02 (0.68-1.54) .93 0.91 (0.60-1.37) .64 
*

Haplotypes with frequencies ≥0.05 are examined. HLA-DPA1∼DPB1 haplotypes were estimated as described previously.22 

Adjusted for stem cell graft source, HLA matching, ABO compatibility, TBI dose, and principal components.

or Create an Account

Close Modal
Close Modal